Back to Search Start Over

Non-dystrophic myotonia Chilean cohort with predominance of the SCN4A Gly1306Glu variant.

Authors :
Avila-Smirnow D
Vargas Leal CP
Beytía Reyes MLA
Cortés Zepeda R
Escobar RG
Kleinsteuber Saa K
Lagos Lucero M
Avaria Benapres MLA
Padilla Pérez O
Casar Leturia JC
Mellado Sagredo C
Sternberg D
Source :
Neuromuscular disorders : NMD [Neuromuscul Disord] 2020 Jul; Vol. 30 (7), pp. 554-561. Date of Electronic Publication: 2020 May 19.
Publication Year :
2020

Abstract

Non-dystrophic myotonias are a group of rare neuromuscular diseases linked to SCN4A or CLCN1. Among the subtypes, myotonia permanens, associated with the Gly1306Glu variant of SCN4A, is a relatively less frequent but more severe form. Most reports of non-dystrophic myotonias describe European populations. Therefore, to expand the genetic and phenotypic spectrum of this disorder, we evaluated 30 Chilean patients with non-dystrophic myotonias for associated variants and clinical characteristics. SCN4A variants were observed in 28 (93%) of patients, including 25 (83%) with myotonia permanens due to the Gly1306Glu variant. Myotonia permanens was inherited in 24 (96%) patients; the mean age of onset was 6 months, and the initial symptoms were orbicularis oculi myotonia in 17 (74%) patients and larynx myotonia in 12 (52%) patients. The extraocular muscles were involved in 11 (44%) patients, upper limbs in 20 (80%), and lower limbs in 21 (84%). Thirteen (52%) patients experienced recurrent pain and 10 (40%) patients reported limitations in daily life activities. Carbamazepine reduced myotonia in eight treated patients. The high frequency of the Gly1306Glu variant in SCN4A in Chilean patients suggests a founder effect and expands its phenotypic spectrum.<br /> (Copyright © 2020 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1873-2364
Volume :
30
Issue :
7
Database :
MEDLINE
Journal :
Neuromuscular disorders : NMD
Publication Type :
Academic Journal
Accession number :
32593548
Full Text :
https://doi.org/10.1016/j.nmd.2020.04.006